
4 September 2026
Scribe starts first-in-human STX-1150 trial
The Phase 1 opened in Australia in mid-2026 in adults with elevated LDL-C and increased ASCVD risk.
The full briefing is in the app.

4 September 2026
The Phase 1 opened in Australia in mid-2026 in adults with elevated LDL-C and increased ASCVD risk.
The full briefing is in the app.